WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) announced April 19 that, following a public comment period, it has approved a final consent order against Telomerase Activation Sciences Inc. and Noel Patton (collectively, TA Sciences) that resolves allegations of deceptive advertising.

TA Sciences marketed that its products, which included capsules, powder and cream, could deliver a broad range of health benefits to consumers. In order to settle the allegations, TA Sciences agreed to stop making false claims about the health benefits, performance, efficacy, safety or side effects of its products. 

Additionally, TA Sciences agreed to other settlement items. It will not misrepresent that any paid commercial advertising is independent programming. It will disclose any material connection between it and any endorsers of its products. Finally, it will not misrepresent that any endorser is an independent user of a product.

The FTC voted 2-0 to approve the final consent order, as well as to send a letter to a member of the public who commented on the order. Andrew Wone of the Bureau of Consumer Protection is staff contact for the case. 

Want to get notified whenever we write about U.S. Federal Trade Commission ?
Next time we write about U.S. Federal Trade Commission , we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

U.S. Federal Trade Commission




More News